Extended RAS Mutational Status Analysis in Circulating Tumor DNA from Patients with Advanced Colorectal Cancer in Daily Clinical Practice. The Franco-British Institute Experience and Recommendations

Laurence Heuls1, Nathalie Perez Staub2, Ida Iurisci1,2, Perrine Goyer1, Arnaud Saget1, Hubert Richa5, Hélène Marijon1, Linda Dainese6, Annette K Larsen7,8, Aimery De Gramont1,2,7,8 and Benoist Chibaudel1,2,7,8

1Department of Clinical and Translational Cancer Research Unit, Franco-British Institute, Levallois Perret, France
2Department of Medical Oncology, Franco-British Institute, Levallois Perret, France
3Department of Gastrointestinal Surgery, Clinique Turin, France
4Department of Gastrointestinal Surgery, Clinique Ambroise Paré, Neuilly Sur Seine, France
5Department of Gastrointestinal Surgery, Franco-British Institute, Levallois Perret, France
6Department of Center of Anatomic Pathology, Institut De Pathologie De Paris, Malakoff, France
7Department of Cancer Biology and Therapeutics, Centre De Recherche Saint-Antoine (CRSA), France
8Institut National de la Santé et de la Recherche Médicale (INSERM) U938, Paris, France

Received: June 25, 2018; Published: July 13, 2018

*Corresponding author: Benoist Chibaudel, Department of Medical Oncology, Franco British Institute, France

Abstract

Background: The development of liquid biopsies could help clinicians to shorten treatment decision and allow longitudinal molecular monitoring. We report here our experience of using the Biocartis Idylla test for patients with advanced colorectal cancer in daily clinical practice.

Patients and Methods: This program prospectively enrolled patients with advanced colorectal cancer at the Department of Medical Oncology of the Franco-British Institute, Levallois-Perret, France. The primary objective was to evaluate the feasibility of the Idylla testing in daily clinical practice.

Results: From November 17, 2017 to June 12, 2018, 50 patients were tested. The median time to circulating tumor (ct) extended mutational status was 4.8 hours (95% CI: 4.7-5.1). Among 37 (74.0%) patients with paired plasma and tumor samples available, the overall agreement rate was 73.0%. In patients with previously untreated metastatic liver disease (n=9; 18%), the overall agreement rate between paired plasma and tumor samples was 100.0%, and the weighted K coefficient was 1.00 (95% CI: 1.00-1.00).

Conclusion: Extended RAS mutational status analysis in circulating tumor DNA from patients with advanced colorectal cancer is feasible and greatly helpful for daily clinical practice. We recommend restricting ctDNA testing with Idylla to patients with previously untreated liver metastatic disease.

Keywords: Colorectal Cancer; Liquid Biopsy; KRAS; NRAS; BRAF

Abbreviations: EGF: Epidermal Growth Factor; MoAb: Monoclonal Antibodies; KRAS: Kirsten Rat Sarcoma Viral Oncogene Homolog; ECD: Extra Cellular Domain; ctDNA: Circulating Tumor DNA; CT: Circulating Tumor

Introduction

Systemic therapy is the standard care for patients with unresectable metastatic colorectal cancer (CRC). Cetuximab and panitumumab are IgG monoclonal antibodies (MoAb), which competitively inhibit the binding of epidermal growth factor (EGF) and other ligands to EGF receptor (EGFR) and downregulate EGFR, resulting in inhibition of cell survival, growth, proliferation, and transformation. Tumor molecular testing for Kirsten rat sarcoma viral oncogene homolog (KRAS) and Neuroblastoma RAS viral oncogene homolog (NRAS) tumor genes is mandatory in order to select MCR patients who may benefit from anti-EGFR MoAb therapy [1]. In 2014, the mean time to obtain the RAS genotyping test report in France was 25 days, and for 25% of the patients it was more than one month [2]. The murine sarcoma viral (v-Raf) oncogene homolog B (BRAF) is a human gene that encodes BRAF, a protein involved in sending signals inside cells, which are involved in directing cell growth. The BRAF V600E mutation is found in 10% of patients with colorectal adenocarcinoma [3] and BRAF mutant tumors are more frequently right-sided, mucinous with peritoneal spreadand microsatellite instability [4].

The extracellular domain (ECD) of EGFR p.S492 mutation has been described as an acquired resistance to cetuximab [5]. The
development of liquid biopsies could help clinicians to shorten treatment decision and allow longitudinal molecular monitoring. The concordance between plasma and tumor RAS mutational status ranges from 84% to 100% depending on different techniques (duplex dPCR, allele specific quantitative PCR, BEAMing [OncoBEAM] or NGS BPER) [6-13]. We report here our experience of using the Biocartis Idylla™ test for daily clinical practice in order to improve care in patients with advanced CRC.

Material and Methods

Study Design and Population

This program prospectively enrolled patients with advanced CRC at the Department of Medical Oncology of the Franco-British Institute, Levallois-Perret, France. Clinical research study nurse was responsible for this program. A signed and dated informed consent form from each patient was required before enrollment.

Methods

The blood sampling was done in the out patient cancer unit, close to the translational research laboratory. EDTA tubes were centrifuged at 1500g for 10 minutes within 4 hours after blood samples collection, the plasma was recovered, and a second centrifugation was performed at 16000g for one minute. Circulating tumor DNA (ctDNA) was extracted and amplified from 1ml of blood plasma. The Idylla™ ctKRAS Mutation Assay is a molecular assay for the qualitative detection of 21 mutations in codons 12, 13, 59, 61, 117 and 146 of the KRAS gene. The Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay is a molecular assay for the semi-quantitative detection of 18 mutations in codons 12, 13, 59, 61, 117, and 146 of the NRAS gene, five mutations in codon 600 of the BRAF gene and two mutations in codon 492 of the EGFR gene. Biocartis Idylla™ platform is a CE-marked IVD in Europe.

Data Collection

Individual patient-level clinical data and tumor mutational RAS and BRAF assessment were collected in DxCare software (©2013 Medasys S.A., Clamart, France). Circulating tumor DNA information was collected using the Idylla™ Explore, a web-based application that allows analyzing data by visualization of PCR curves from the Idylla™ tests results, Cq values per target, and direct access to console results report.

Statistical Analysis

The primary objective was to evaluate the feasibility of the Idylla™ testing in daily clinical practice. Secondary objectives were:

a) To evaluate the accuracy of RAS and BRAF status between paired plasma and tumor samples

b) To compare the time to molecular mutational diagnosis between tumor and plasma techniques in patients with initially unknown tumor status

c) To evaluate the incidence of neomutations in patients with wild-type CRC treated with anti-EGFR MoAb using a serial tracking of KRAS, NRAS, BRAF, and EFGR mutations

d) To evaluate the incidence of mutation loss in patients with mutated RAS or BRAF CRC.

The feasibility of the Idylla™ testing was calculated using the time from blood sample collection to the Idylla™ processing and results. The accuracy was calculated using the interrate agreement kappa(K) coefficient [14] with its 95% circulating tumor. The strength of agreement was interpreted according to K value as follows: poor (<0.20), fair (0.21-0.40), moderate (0.41-0.60), good (0.61-0.80), and very good (0.81-1.00). All analyses were performed using MedCalc Statistical Software version 18.2.1 (MedCalc Software bvba, Ostend, Belgium, http://www.medcalc.org; 2018).

Results

Patient Characteristics

From November 17, 2017 to June 12, 2018, 50 patients with advanced CRC had their tumor genotyped by the Idylla™ test. This testing was proposed to 30 (60.0%) patients with unknown or partially known RAS/BRAF tumor status and to 20 (40.0%) patients with known status for the RAS and BRAF tumor genes (Table 1) and (Figure 1). The mean age was 67.9 years (range: 29.7-93.4). The IdyllaTM test was done in 33(66.0%) patients before starting a new treatment sequence and in 17 (34.0%) patients with ongoing treatment sequence.
### Table 1: Patient characteristics, n (%).

<table>
<thead>
<tr>
<th></th>
<th>All n=50</th>
<th>Unknown or Partial Tumor Mutational status n=30</th>
<th>Known Tumor Mutational Status n=20</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>28</td>
<td>13</td>
<td>15</td>
</tr>
<tr>
<td>Female</td>
<td>22</td>
<td>17</td>
<td>5</td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;70</td>
<td>28</td>
<td>17</td>
<td>11</td>
</tr>
<tr>
<td>≥70</td>
<td>22</td>
<td>13</td>
<td>9</td>
</tr>
<tr>
<td><strong>RAS/BRAF tumor mutational status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild-type</td>
<td>20</td>
<td>8</td>
<td>12</td>
</tr>
<tr>
<td>Mutant</td>
<td>17</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>Unknown</td>
<td>13</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td><strong>Primary tumor location</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right</td>
<td>13</td>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td>Left</td>
<td>25</td>
<td>14</td>
<td>11</td>
</tr>
<tr>
<td>Rectum</td>
<td>11</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>Unknown or missing</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td><strong>Prior primary tumor resection</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>25</td>
<td>19</td>
<td>6</td>
</tr>
<tr>
<td>Yes</td>
<td>25</td>
<td>11</td>
<td>14</td>
</tr>
<tr>
<td><strong>No. of metastatic sites</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>1</td>
<td>23</td>
<td>17</td>
<td>6</td>
</tr>
<tr>
<td>≥2</td>
<td>24</td>
<td>11</td>
<td>13</td>
</tr>
<tr>
<td><strong>Metastatic sites</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>34</td>
<td>20</td>
<td>14</td>
</tr>
<tr>
<td>Lung</td>
<td>19</td>
<td>9</td>
<td>10</td>
</tr>
<tr>
<td>Nodes</td>
<td>8</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Peritoneum</td>
<td>14</td>
<td>8</td>
<td>6</td>
</tr>
</tbody>
</table>

**Feasibility of the Idylla™ Testing**

Seventy three samples analyses (including longitudinal testing) were performed. ctKRAS mutation assay was done in 73 samples and ctNRAS/BRAF/EGFR mutation assay was performed for 60 samples. The median time from blood sample collection to the Idylla™ processing was 34 minutes (95% CI: 29-39). The median time to ctKRAS results and to full ctKRAS/NRAS/BRAF/EGFR results were 2.8 hours (95% CI: 2.7-2.9) and 4.8 hours (95% CI: 4.7-5.1), respectively.

**Time to Molecular Mutational Diagnosis: Plasma vs Tumor**

In 30 (60%) patients with initially unknown tumor status, the median time to molecular profile using liquid biopsies was 4.8 hours (range:2.5-65.6). At the time of analysis, the tumor molecular profile was obtained in 17 (56.7%) patients, in whom the median time to a full molecular diagnosis was 56.0 days (95% CI: 35.1-83.9).
Accuracy of RAS and BRAF Status Between Paired Plasma and Tumor Samples

Among 37 (74.0%) patients with paired plasma and tumor samples available, 27 (73.0%) had a concordant molecular profile between plasma and tumor. Positive, negative, and overall agreement rates were 47.0%, 95.0% and 73.0%, respectively. The weighted K coefficient was 0.44 (95% CI: 0.17-0.70). Among 10 (20%) patients with discordant results between plasma and tumor, five patients had single extra-liver metastatic site (lung, n=3; peritoneum, n=2) and five patients received prior therapy for metastatic disease (n=9; 18%). There were no discordant results between plasma and tumor. The positive, negative and overall agreement rates were 100.0%, and the weighted K coefficient was 1.00 (95% CI: 1.00-1.00).

Table 2: Discordant results, n=10.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Tumor</th>
<th>Plasma</th>
<th>Sidedness</th>
<th>Primary Tumor</th>
<th>Time to Met.</th>
<th>No. of Sites</th>
<th>Liver</th>
<th>No. of Lines</th>
</tr>
</thead>
<tbody>
<tr>
<td>BR260332-01</td>
<td>Mut KRAS</td>
<td>ctWT</td>
<td>Unknown</td>
<td>Not resected</td>
<td>Synchronous</td>
<td>1</td>
<td>No</td>
<td>1</td>
</tr>
<tr>
<td>CM171250-01</td>
<td>Mut KRAS</td>
<td>ctWT</td>
<td>Right</td>
<td>Resected</td>
<td>Synchronous</td>
<td>3</td>
<td>Yes</td>
<td>2</td>
</tr>
<tr>
<td>DF280249-01</td>
<td>Mut KRAS</td>
<td>ctWT</td>
<td>Right</td>
<td>Not resected</td>
<td>Synchronous</td>
<td>2</td>
<td>Yes</td>
<td>1</td>
</tr>
<tr>
<td>LJ080777-01</td>
<td>Mut KRAS</td>
<td>ctWT</td>
<td>Left</td>
<td>Resected</td>
<td>Synchronous</td>
<td>3</td>
<td>Yes</td>
<td>3</td>
</tr>
<tr>
<td>LO080230-01</td>
<td>Mut KRAS</td>
<td>ctWT</td>
<td>Left</td>
<td>Resected</td>
<td>Synchronous</td>
<td>1</td>
<td>No</td>
<td>1</td>
</tr>
<tr>
<td>DJ280440-01</td>
<td>Mut KRAS</td>
<td>ctWT</td>
<td>Rectum</td>
<td>Resected</td>
<td>Metachronous</td>
<td>1</td>
<td>No</td>
<td>0</td>
</tr>
<tr>
<td>GD060951-01</td>
<td>Mut KRAS</td>
<td>ctWT</td>
<td>Rectum</td>
<td>Not resected</td>
<td>Synchronous</td>
<td>1</td>
<td>No</td>
<td>1</td>
</tr>
<tr>
<td>TM311234-01</td>
<td>Mut KRAS</td>
<td>ctWT</td>
<td>Rectum</td>
<td>Resected</td>
<td>Metachronous</td>
<td>3</td>
<td>Yes</td>
<td>3</td>
</tr>
<tr>
<td>JP220454-01</td>
<td>Mut BRAF</td>
<td>ctWT</td>
<td>Left</td>
<td>Resected</td>
<td>Metachronous</td>
<td>1</td>
<td>No</td>
<td>3</td>
</tr>
<tr>
<td>YM221242-01</td>
<td>WT</td>
<td>ctMut KRAS</td>
<td>Left</td>
<td>Resected</td>
<td>Metachronous</td>
<td>2</td>
<td>Yes</td>
<td>1</td>
</tr>
</tbody>
</table>

Neomutations in Wild-Type Crc Patients

Of the nine (18%) patients with wild-type RAS/RAF CRC treated with anti-EGFR MoAb using a serial tracking of KRAS, NRAS, BRAF and EGF mutations, two (22.2%) had neomutations. The first patient was treated with FOLFIRI-cetuximab as first-line therapy for right-sided unresectable metastatic CRC. A ctNRAS G12A/V neomutation was not confirmed in further liquid biopsy and was contemporary of partial response (Figure 2A). The second patient was treated with cetuximab-irinotecan as third line therapy for left sided metastatic CRC. A ctKRAS G12C neomutation was confirmed in further liquid biopsy and preceded radiologic disease progression (Figure 2B). Of note, an EGFR S492R mutation was found in one patient with locally advanced right-sided KRAS wild-type CRC (insufficient tumor material for NRAS and BRAF analysis). This patient received prior FOLFOX first-line therapy without anti-EGFR MoAb. In this patient, panitumumab was preferred to cetuximab as second-line therapy due to the mutation of the extracellular domain of EGFR. Panitumumab was stopped after 3 cycles due to clinical and biological (CEA) progression while CT-scan stabilization was observed.

Loss of Mutation in Mutant CRC Patients

Of the eight (16%) patients with previously treated (i.e., at least one prior line of therapy) mutant RAS or BRAF metastatic CRC, six patients were ctRAS/RAF wild-type and two patients were ctRAS or ctBRAF mutant.

Discussion

This is the first prospective report of using the Idylla™ ctKRAS and ctNRAS/BRAF/EGFR testing for patients with advanced CRC in daily clinical practice. Clinical research study nurse was responsible for this program. Blood sampling was located close to the translational research laboratory inorder to shorten the preanalytical time, with a median time from sample collection to the Idylla™ processing of 34 minutes, including the centrifugation process. Molecular diagnostic testing of four genes (KRAS, NRAS, BRAF and EGFR) took less than 5 hours, enabling physicians to make timely therapeutic decisions, and compare favorably with 56 days necessary to obtain a full tumor molecular evaluation.
the unselected population, the overall agreement between plasma and tumor was 73%. Discordant results were observed in patients with extra-liver disease and/or in patients having received prior therapy for metastatic disease. Thus, when aimed to obtain a rapid molecular diagnosis, the Idylla™ testing should be restricted to patients with previously untreated CRC with liver metastasis, with an overall agreement rate of 100%. Serial tracking of the RAS and BRAF mutation emergence in patients with wild-type CRC treated with anti-EGFR MoAb was previously described [15].

In our study, a transient ctNRAS mutation was found in one patient treated with cetuximab-based therapy, but was not associated with disease progression, whereas a confirmed ctKRAS mutation preceded failure of cetuximab-based therapy. Liquid biopsy could help to identify patients having tumors with secondary resistance to drugs and to develop different treatment strategies using agents targeting neomutations for those patients. Serial tracking of the RAS or BRAF mutation loss may also be offered to patients with mutant RAS or BRAF CRC. It has been previously suggested that patients with metastatic CRC harboring mutated primary tumors, thus not candidate to EGFR MoAb, frequently have wild-type RAS circulating tumor cells in blood [16]. Preliminary data suggest that patients with mutant KRAS CRC can frequently (50%) switch to a prevalent wild-type KRAS disease in course of treatment with anti-angiogenic drugs [17]. This phenomenon was concomitant to disease progression. In our series, six of the eight patients with previously treated mutant RAS or BRAF metastatic CRC were ct wild-type. Those ‘NeoWild-Type’ patients may be eligible to anti-EGFR therapy and warrant larger prospective evaluation in this particular setting.

Conclusion

Extended RAS mutational status analysis in circulating tumor DNA from patients with advanced CRC is feasible and helpful for daily practice routine. We recommend restricting the Idylla™ ctDNA testing to patients with previously untreated liver metastatic disease.

Acknowledgment

We thank Dr. Magdalena Benetliewicz for help in editing the manuscript and Mr. Sébastien Le Maner and Ms. Nathalie Vandenbossche (Merck, France) for partnership.

Key Message

We evaluated the feasibility of plasma RAS and BRAF analysis of patients with advanced colorectal cancer in daily routine clinical practice. The Idylla™ testing provided sameday results (within 5 hours) enabling physicians to make timely therapeutic decisions. We recommend restricting ctDNA testing to patients with previously untreated liver metastatic disease.

Fundings:

The Idylla™ console was provided by Biocartis.

This program was supported by a grant from Merck France [affiliate of Merck KGaA (Darmstadt, Germany)] to Franco-British Institute, France.

References


ISSN: 2574-1241

DOI: 10.26717/BJSTR.2018.06.001409

Benoist Chibaudel, Biomed J Sci & Tech Res

This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: https://biomedres.us/submit-manuscript.php

Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

https://biomedres.us/